{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:28:59Z","timestamp":1789118939878,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100017534","name":"Inner Mongolia Medical University","doi-asserted-by":"publisher","award":["Grant No. 2025YFDZ0139"],"award-info":[{"award-number":["Grant No. 2025YFDZ0139"]}],"id":[{"id":"10.13039\/100017534","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-026-06593-8","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:34:26Z","timestamp":1786631666000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune-sparing radiotherapy in solid tumors: radiation-induced lymphopenia, circulating immune-cell dose, and biomarker-guided optimization of radioimmunotherapy"],"prefix":"10.1007","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4216-8592","authenticated-orcid":false,"given":"Shiduo","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Erdemutu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaochu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5446-6718","authenticated-orcid":false,"given":"Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"6593_CR1","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.jtho.2020.06.008","volume":"15","author":"A Abravan","year":"2020","unstructured":"Abravan A, Faivre-Finn C, Kennedy J, McWilliam A, van Herk M (2020) Radiotherapy-related lymphopenia affects overall survival in patients with lung cancer. J Thorac Oncol 15:1624\u20131635. https:\/\/doi.org\/10.1016\/j.jtho.2020.06.008","journal-title":"J Thorac Oncol"},{"key":"6593_CR2","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D et al (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377:1919\u20131929. https:\/\/doi.org\/10.1056\/NEJMoa1709937","journal-title":"N Engl J Med"},{"key":"6593_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.phro.2022.07.006","volume":"23","author":"M Bar\u00e9","year":"2022","unstructured":"Bar\u00e9 M, Poeta S, Fernandes P et al (2022) Lymphocyte-sparing pelvic radiotherapy for prostate cancer: an in-silico study. Phys Imaging Radiat Oncol 23:127\u2013133. https:\/\/doi.org\/10.1016\/j.phro.2022.07.006","journal-title":"Phys Imaging Radiat Oncol"},{"key":"6593_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","volume":"9","author":"A Bartolomucci","year":"2025","unstructured":"Bartolomucci A, Nobrega M, Ferrier T et al (2025) Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. NPJ Precis Oncol 9:84. https:\/\/doi.org\/10.1038\/s41698-025-00876-y","journal-title":"NPJ Precis Oncol"},{"key":"6593_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2019.01.018","volume":"134","author":"J Biau","year":"2019","unstructured":"Biau J, Lapeyre M, Troussier I et al (2019) Selection of lymph node target volumes for definitive head and neck radiation therapy: a 2019 update. Radiother Oncol 134:1\u20139. https:\/\/doi.org\/10.1016\/j.radonc.2019.01.018","journal-title":"Radiother Oncol"},{"key":"6593_CR6","doi-asserted-by":"publisher","DOI":"10.1080\/01443615.2023.2194991","volume":"43","author":"H Cao","year":"2023","unstructured":"Cao H, Yan H, Bai S, Gu B (2023) Radiation-induced lymphopenia and the survival of women with cervical cancer: a meta-analysis. J Obstet Gynaecol 43:2194991. https:\/\/doi.org\/10.1080\/01443615.2023.2194991","journal-title":"J Obstet Gynaecol"},{"key":"6593_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.110041","volume":"190","author":"L Cella","year":"2024","unstructured":"Cella L, Monti S, Pacelli R, Palma G (2024) Modeling frameworks for radiation induced lymphopenia: a critical review. Radiother Oncol 190:110041. https:\/\/doi.org\/10.1016\/j.radonc.2023.110041","journal-title":"Radiother Oncol"},{"key":"6593_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13014-026-02791-3","volume":"21","author":"YC Cheng","year":"2026","unstructured":"Cheng YC, Huang WY, Shen PC et al (2026) Radiation-induced severe lymphopenia predicts distant metastasis in rectal cancer: dosimetric implications for immune-sparing radiotherapy. Radiat Oncol 21:34. https:\/\/doi.org\/10.1186\/s13014-026-02791-3","journal-title":"Radiat Oncol"},{"key":"6593_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2022.01.007","volume":"168","author":"Y Cho","year":"2022","unstructured":"Cho Y, Kim Y, Chamseddine I et al (2022) Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy. Radiother Oncol 168:1\u20137. https:\/\/doi.org\/10.1016\/j.radonc.2022.01.007","journal-title":"Radiother Oncol"},{"key":"6593_CR10","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.ijrobp.2024.05.018","volume":"120","author":"Y Chu","year":"2024","unstructured":"Chu Y, Zhu C, Hobbs BP et al (2024) Personalized composite dosimetric score-based machine learning model of severe radiation-induced lymphopenia among patients with esophageal cancer. Int J Radiat Oncol Biol Phys 120:1172\u20131180. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.05.018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6593_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14123024","volume":"14","author":"D Dai","year":"2022","unstructured":"Dai D, Tian Q, Yu G, Shui Y, Jiang H, Wei Q (2022a) Severe radiation-induced lymphopenia affects the outcomes of esophageal cancer: a comprehensive systematic review and meta-analysis. Cancers 14:3024. https:\/\/doi.org\/10.3390\/cancers14123024","journal-title":"Cancers"},{"key":"6593_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.radonc.2022.01.003","volume":"168","author":"D Dai","year":"2022","unstructured":"Dai D, Tian Q, Shui Y, Li J, Wei Q (2022b) The impact of radiation induced lymphopenia in the prognosis of head and neck cancer: a systematic review and meta-analysis. Radiother Oncol 168:28\u201336. https:\/\/doi.org\/10.1016\/j.radonc.2022.01.003","journal-title":"Radiother Oncol"},{"key":"6593_CR13","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.ijrobp.2021.07.1695","volume":"111","author":"PJJ Damen","year":"2021","unstructured":"Damen PJJ, Kroese TE, van Hillegersberg R et al (2021) The influence of severe radiation-induced lymphopenia on overall survival in solid tumors: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 111:936\u2013948. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.07.1695","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6593_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34676-w","volume":"13","author":"LB Darragh","year":"2022","unstructured":"Darragh LB, Gadwa J, Pham TT et al (2022) Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors. Nat Commun 13:7015. https:\/\/doi.org\/10.1038\/s41467-022-34676-w","journal-title":"Nat Commun"},{"key":"6593_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.110907","volume":"208","author":"CS Dejonckheere","year":"2025","unstructured":"Dejonckheere CS, Nour Y, Sahlmann J et al (2025) Impact of estimated dose of radiation to immune cells (EDRIC) in locally advanced non-small-cell lung cancer: a secondary analysis of the multicenter randomized PET-Plan trial. Radiother Oncol 208:110907. https:\/\/doi.org\/10.1016\/j.radonc.2025.110907","journal-title":"Radiother Oncol"},{"key":"6593_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.14338\/IJPT-20-00086","volume":"8","author":"S Ebrahimi","year":"2021","unstructured":"Ebrahimi S, Lim G, Liu A et al (2021) Radiation-induced lymphopenia risks of photon versus proton therapy for esophageal cancer patients. Int J Part Ther 8:17\u201327. https:\/\/doi.org\/10.14338\/IJPT-20-00086","journal-title":"Int J Part Ther"},{"issue":"2","key":"6593_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2022.101038","volume":"8","author":"Y El Houat","year":"2023","unstructured":"El Houat Y, Massard C, Quillien V, de Crevoisier R, Castelli J (2023) Meta-analysis and critical review: association between radio-induced lymphopenia and overall survival in solid cancers. Adv Radiat Oncol 8(2):101038. https:\/\/doi.org\/10.1016\/j.adro.2022.101038","journal-title":"Adv Radiat Oncol"},{"key":"6593_CR18","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.adro.2018.08.014","volume":"3","author":"SG Ellsworth","year":"2018","unstructured":"Ellsworth SG (2018) Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors. Adv Radiat Oncol 3:512\u2013519. https:\/\/doi.org\/10.1016\/j.adro.2018.08.014","journal-title":"Adv Radiat Oncol"},{"key":"6593_CR19","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jnci\/djs629","volume":"105","author":"SC Formenti","year":"2013","unstructured":"Formenti SC, Demaria S (2013) Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 105:256\u2013265. https:\/\/doi.org\/10.1093\/jnci\/djs629","journal-title":"J Natl Cancer Inst"},{"key":"6593_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.110030","volume":"190","author":"C Friedes","year":"2024","unstructured":"Friedes C, Iocolano M, Lee SH et al (2024) The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC. Radiother Oncol 190:110030. https:\/\/doi.org\/10.1016\/j.radonc.2023.110030","journal-title":"Radiother Oncol"},{"key":"6593_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.semradonc.2014.07.005","volume":"25","author":"EB Golden","year":"2015","unstructured":"Golden EB, Apetoh L (2015) Radiotherapy and immunogenic cell death. Semin Radiat Oncol 25:11\u201317. https:\/\/doi.org\/10.1016\/j.semradonc.2014.07.005","journal-title":"Semin Radiat Oncol"},{"key":"6593_CR22","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.1158\/1078-0432.CCR-11-0774","volume":"17","author":"SA Grossman","year":"2011","unstructured":"Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S, Piantadosi S, NABTT CNS Consortium (2011) Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res 17:5473\u20135480. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0774","journal-title":"Clin Cancer Res"},{"key":"6593_CR23","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6560\/ab6c41","volume":"65","author":"A Hammi","year":"2020","unstructured":"Hammi A, Paganetti H, Grassberger C (2020) Four-dimensional blood flow model for dose calculation to circulating blood and lymphocytes. Phys Med Biol 65:055008. https:\/\/doi.org\/10.1088\/1361-6560\/ab6c41","journal-title":"Phys Med Biol"},{"key":"6593_CR24","doi-asserted-by":"publisher","first-page":"6193","DOI":"10.3390\/cancers13246193","volume":"13","author":"JY Jin","year":"2021","unstructured":"Jin JY, Hu C, Xiao Y et al (2021) Higher radiation dose to immune cells correlates with poor tumor control and overall survival in patients with stage III NSCLC: a secondary analysis of RTOG 0617. Cancers 13:6193. https:\/\/doi.org\/10.3390\/cancers13246193","journal-title":"Cancers"},{"key":"6593_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100391","volume":"3","author":"W Jing","year":"2022","unstructured":"Jing W, Xu T, Wu L et al (2022) Severe radiation-induced lymphopenia attenuates the benefit of durvalumab after concurrent chemoradiotherapy for NSCLC. JTO Clin Res Rep 3:100391. https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100391","journal-title":"JTO Clin Res Rep"},{"key":"6593_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2023.100505","volume":"4","author":"T Kuge","year":"2023","unstructured":"Kuge T, Shiroyama T, Tamiya A et al (2023) Impact of lymphopenia recovery after chemoradiotherapy on durvalumab consolidation therapy in stage III NSCLC. JTO Clin Res Rep 4:100505. https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100505","journal-title":"JTO Clin Res Rep"},{"key":"6593_CR27","doi-asserted-by":"publisher","first-page":"1426635","DOI":"10.3389\/fimmu.2024.1426635","volume":"15","author":"L Kuncman","year":"2024","unstructured":"Kuncman L, Pajdzinski M, Smolka K et al (2024) Early lymphocyte levels and low doses radiation exposure of lung predict lymphopenia in radiotherapy for lung cancer. Front Immunol 15:1426635. https:\/\/doi.org\/10.3389\/fimmu.2024.1426635","journal-title":"Front Immunol"},{"key":"6593_CR28","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ijrobp.2019.05.064","volume":"105","author":"CJ Ladbury","year":"2019","unstructured":"Ladbury CJ, Rusthoven CG, Camidge DR, Kavanagh BD, Nath SK (2019) Impact of radiation dose to the host immune system on tumor control and survival for stage III non-small cell lung cancer treated with definitive radiation therapy. Int J Radiat Oncol Biol Phys 105:346\u2013355. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.05.064","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6593_CR29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.semradonc.2019.12.003","volume":"30","author":"P Lambin","year":"2020","unstructured":"Lambin P, Lieverse RIY, Eckert F et al (2020) Lymphocyte-sparing radiotherapy: the rationale for protecting lymphocyte-rich organs when combining radiotherapy with immunotherapy. Semin Radiat Oncol 30:187\u2013193. https:\/\/doi.org\/10.1016\/j.semradonc.2019.12.003","journal-title":"Semin Radiat Oncol"},{"key":"6593_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ctro.2022.07.007","volume":"36","author":"SF Lee","year":"2022","unstructured":"Lee SF, Yip PL, Wong A et al (2022) Splenic irradiation contributes to grade \u22653 lymphopenia after adjuvant chemoradiation for stomach cancer. Clin Transl Radiat Oncol 36:83\u201390. https:\/\/doi.org\/10.1016\/j.ctro.2022.07.007","journal-title":"Clin Transl Radiat Oncol"},{"key":"6593_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-025-02652-5","volume":"20","author":"S Lee","year":"2025","unstructured":"Lee S, Kim S, Ha S et al (2025) Exploring the impact of pelvic radiotherapy dose distribution on lymphocyte counts: a voxel-based analysis. Radiat Oncol 20:92. https:\/\/doi.org\/10.1186\/s13014-025-02652-5","journal-title":"Radiat Oncol"},{"key":"6593_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1459206","volume":"15","author":"J Li","year":"2024","unstructured":"Li J, Chen Q, Liu Z et al (2024) Predictive value of bowel dose-volume for severe radiation-induced lymphopenia and survival in cervical cancer. Front Immunol 15:1459206. https:\/\/doi.org\/10.3389\/fimmu.2024.1459206","journal-title":"Front Immunol"},{"key":"6593_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.22964","volume":"33","author":"J Liu","year":"2019","unstructured":"Liu J, Li S, Zhang S et al (2019) Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. J Clin Lab Anal 33:e22964. https:\/\/doi.org\/10.1002\/jcla.22964","journal-title":"J Clin Lab Anal"},{"key":"6593_CR34","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-17-3427","volume":"24","author":"AE Marciscano","year":"2018","unstructured":"Marciscano AE, Ghasemzadeh A, Nirschl TR et al (2018) Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy. Clin Cancer Res 24:5058\u20135071. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3427","journal-title":"Clin Cancer Res"},{"key":"6593_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2025.103873","volume":"44","author":"TA Mickel","year":"2025","unstructured":"Mickel TA, Moon DH, Avkshtol V, Pham NL, Shah JL, Hughes RS, Sumer BD, Sher DJ (2025) Relationship between elective neck irradiation and severe lymphopenia in patients treated with head and neck chemoradiotherapy. Clin Oncol (r Coll Radiol) 44:103873. https:\/\/doi.org\/10.1016\/j.clon.2025.103873","journal-title":"Clin Oncol (r Coll Radiol)"},{"key":"6593_CR36","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/neuonc\/noaa182","volume":"23","author":"R Mohan","year":"2021","unstructured":"Mohan R, Liu AY, Brown PD et al (2021) Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons. Neuro Oncol 23:284\u2013294. https:\/\/doi.org\/10.1093\/neuonc\/noaa182","journal-title":"Neuro Oncol"},{"key":"6593_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1201500","volume":"13","author":"H Paganetti","year":"2023","unstructured":"Paganetti H (2023) A review on lymphocyte radiosensitivity and its impact on radiotherapy. Front Oncol 13:1201500. https:\/\/doi.org\/10.3389\/fonc.2023.1201500","journal-title":"Front Oncol"},{"key":"6593_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.763790","volume":"11","author":"Y Peng","year":"2021","unstructured":"Peng Y, Mei W, Ma K, Zeng C (2021) Circulating tumor DNA and minimal residual disease in solid tumors: current horizons and future perspectives. Front Oncol 11:763790. https:\/\/doi.org\/10.3389\/fonc.2021.763790","journal-title":"Front Oncol"},{"key":"6593_CR39","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ijrobp.2018.09.010","volume":"103","author":"LRG Pike","year":"2019","unstructured":"Pike LRG, Bang A, Mahal BA et al (2019) The impact of radiation therapy on lymphocyte count and survival in metastatic cancer patients receiving PD-1 immune checkpoint inhibitors. Int J Radiat Oncol Biol Phys 103:142\u2013151. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.09.010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6593_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2024.100852","volume":"49","author":"E Prades-Sagarra","year":"2024","unstructured":"Prades-Sagarra E, Yaromina A, Dubois LJ (2024) Understanding the impact of radiation-induced lymphopenia: preclinical and clinical research perspectives. Clin Transl Radiat Oncol 49:100852. https:\/\/doi.org\/10.1016\/j.ctro.2024.100852","journal-title":"Clin Transl Radiat Oncol"},{"key":"6593_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1066255","volume":"14","author":"J Qiu","year":"2023","unstructured":"Qiu J, Lin H, Ke D et al (2023) Higher radiation dose on immune cells is associated with radiation-induced lymphopenia and worse prognosis in patients with locally advanced esophageal squamous cell carcinoma. Front Immunol 14:1066255. https:\/\/doi.org\/10.3389\/fimmu.2023.1066255","journal-title":"Front Immunol"},{"key":"6593_CR42","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41590-019-0561-4","volume":"21","author":"ME Rodriguez-Ruiz","year":"2020","unstructured":"Rodriguez-Ruiz ME, Rodriguez I, Mayorga L et al (2020) Immunological impact of cell death signaling driven by radiation on the tumor microenvironment. Nat Immunol 21:120\u2013134. https:\/\/doi.org\/10.1038\/s41590-019-0561-4","journal-title":"Nat Immunol"},{"key":"6593_CR43","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13014-023-02393-3","volume":"19","author":"AM Saeed","year":"2024","unstructured":"Saeed AM, Bentzen SM, Ahmad H, Pham L, Woodworth GF, Mishra MV (2024) Systematic review and pooled analysis of the impact of treatment-induced lymphopenia on survival of glioblastoma patients. Radiat Oncol 19:36. https:\/\/doi.org\/10.1186\/s13014-023-02393-3","journal-title":"Radiat Oncol"},{"key":"6593_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2025.101071","volume":"56","author":"V Sandul","year":"2026","unstructured":"Sandul V, Al-Hamami SS, Kube\u0161 J, Durante M, Friedrich T (2026) Radiation-induced lymphopenia: a data compilation to unveil relevant factors and mitigation strategies. Clin Transl Radiat Oncol 56:101071. https:\/\/doi.org\/10.1016\/j.ctro.2025.101071","journal-title":"Clin Transl Radiat Oncol"},{"key":"6593_CR45","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, Faivre-Finn C, Gray JE et al (2022) Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol 40:1301\u20131311. https:\/\/doi.org\/10.1200\/JCO.21.01308","journal-title":"J Clin Oncol"},{"key":"6593_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49873-y","volume":"15","author":"I Telarovic","year":"2024","unstructured":"Telarovic I, Yong CSM, Kurz L et al (2024) Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease. Nat Commun 15:5500. https:\/\/doi.org\/10.1038\/s41467-024-49873-y","journal-title":"Nat Commun"},{"key":"6593_CR47","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13014-023-02354-w","volume":"18","author":"I Tseng","year":"2023","unstructured":"Tseng I, Ai D, Chen Y, Zhu H, Li F, Xu Y, Yu L, Liu Q, Deng J, Hao S, Zhu Z, Zhao W, Fan M, Li L, Su F, Zhao K (2023) Lymphocyte recovery from radiation-induced lymphopenia in locally advanced esophageal squamous cell carcinoma: correlations with prognosis and lymphocyte-related organs. Radiat Oncol 18:172. https:\/\/doi.org\/10.1186\/s13014-023-02354-w","journal-title":"Radiat Oncol"},{"key":"6593_CR48","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.radonc.2021.01.034","volume":"157","author":"R Upadhyay","year":"2021","unstructured":"Upadhyay R, Venkatesulu BP, Giridhar P et al (2021) Risk and impact of radiation related lymphopenia in lung cancer: a systematic review and meta-analysis. Radiother Oncol 157:225\u2013233. https:\/\/doi.org\/10.1016\/j.radonc.2021.01.034","journal-title":"Radiother Oncol"},{"key":"6593_CR49","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.ijrobp.2026.02.238","volume":"125","author":"PSN van Rossum","year":"2026","unstructured":"van Rossum PSN, Damen PJJ, Cortiula F et al (2026) Pretreatment risk model for radiation-induced lymphopenia is associated with adjuvant durvalumab efficacy in patients with unresectable stage III NSCLC. Int J Radiat Oncol Biol Phys 125:1434\u20131444. https:\/\/doi.org\/10.1016\/j.ijrobp.2026.02.238","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6593_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ et al (2017) DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun 8:15618. https:\/\/doi.org\/10.1038\/ncomms15618","journal-title":"Nat Commun"},{"key":"6593_CR51","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2217\/fon-2021-0483","volume":"18","author":"BP Venkatesulu","year":"2022","unstructured":"Venkatesulu BP, Chan DP, Giridhar P et al (2022) A systematic review and meta-analysis of the impact of radiation-related lymphopenia on outcomes in pancreatic cancer. Future Oncol 18:1885\u20131895. https:\/\/doi.org\/10.2217\/fon-2021-0483","journal-title":"Future Oncol"},{"key":"6593_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6220-1","volume":"19","author":"G Wu","year":"2019","unstructured":"Wu G, Baine MJ, Zhao N et al (2019) Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer. BMC Cancer 19:977. https:\/\/doi.org\/10.1186\/s12885-019-6220-1","journal-title":"BMC Cancer"},{"key":"6593_CR53","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.radonc.2020.02.015","volume":"146","author":"C Xu","year":"2020","unstructured":"Xu C, Jin JY, Zhang M et al (2020) The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy. Radiother Oncol 146:180\u2013186. https:\/\/doi.org\/10.1016\/j.radonc.2020.02.015","journal-title":"Radiother Oncol"},{"key":"6593_CR54","doi-asserted-by":"publisher","first-page":"e425","DOI":"10.1002\/onco.13533","volume":"26","author":"H Xu","year":"2021","unstructured":"Xu H, Lin M, Hu Y et al (2021) Lymphopenia during definitive chemoradiotherapy in esophageal squamous cell carcinoma: association with dosimetric parameters and patient outcomes. Oncologist 26:e425\u2013e435. https:\/\/doi.org\/10.1002\/onco.13533","journal-title":"Oncologist"},{"key":"6593_CR55","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/978-3-030-38862-1_10","volume":"180","author":"T Yamazaki","year":"2020","unstructured":"Yamazaki T, Vanpouille-Box C, Demaria S, Galluzzi L (2020) Immunogenic cell death driven by radiation-impact on the tumor microenvironment. Cancer Treat Res 180:281\u2013296. https:\/\/doi.org\/10.1007\/978-3-030-38862-1_10","journal-title":"Cancer Treat Res"},{"key":"6593_CR56","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.ijrobp.2024.04.003","volume":"120","author":"G Yang","year":"2024","unstructured":"Yang G, Koom WS, Lee BM et al (2024) Reduced risk of severe radiation-induced lymphopenia in carbon ion radiation therapy for locally advanced pancreatic cancer: a comparative analysis of carbon versus photon therapy. Int J Radiat Oncol Biol Phys 120:544\u2013554. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.04.003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6593_CR57","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3109\/07357907.2012.762780","volume":"31","author":"S Yovino","year":"2013","unstructured":"Yovino S, Kleinberg L, Grossman SA et al (2013) The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Invest 31:140\u2013144. https:\/\/doi.org\/10.3109\/07357907.2012.762780","journal-title":"Cancer Invest"},{"key":"6593_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12531-z","volume":"24","author":"M Zhang","year":"2024","unstructured":"Zhang M, Li Z, Yin Y (2024) Association of effective dose to immune cells and vertebral marrow dose with hematologic toxicity during neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma. BMC Cancer 24:779. https:\/\/doi.org\/10.1186\/s12885-024-12531-z","journal-title":"BMC Cancer"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06593-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06593-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06593-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:05:05Z","timestamp":1789117505000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-026-06593-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":58,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["6593"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06593-8","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"26 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"177"}}